Infinity Pharmaceuticals (INFI) reported quarterly earnings results on Wednesday, May-4-2016. The company reported $-0.82 EPS for the quarter. Analysts had a consensus estimate of $-0.82. The company posted revenue of $9.26 million in the period, compared to analysts expectations of $8.93 million. The company’s revenue was up 112.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-1.91 EPS.
Many Wall Street Analysts have commented on Infinity Pharmaceuticals. FBR Capital Initiated Infinity Pharmaceuticals on Mar 2, 2016 to “Outperform”, Price Target of the shares are set at $15.Shares were Reiterated by Wedbush on Feb 25, 2016 to “Neutral” and Lowered the Price Target to $ 8 from a previous price target of $9 .
Infinity Pharmaceuticals opened for trading at $5.85 and hit $5.98 on the upside on Monday, eventually ending the session at $5.87, with a gain of 1.21% or 0.07 points. The heightened volatility saw the trading volume jump to 3,45,870 shares. Company has a market cap of $290 M.
In a different news, on Jun 26, 2015, Adelene Q Perkins (President & CEO) sold 5,000 shares at $10.93 per share price. According to the SEC, on Jun 16, 2015, Vito J. Palombella (Chief Scientific Officer) sold 4,737 shares at $10.97 per share price.
Infinity Pharmaceuticals Inc. is a biopharmaceutical company that is engaged in the discovery development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target emerging disease pathways for potential applications in oncology. Its most advanced product candidate is duvelisib also known as IPI-145 an oral dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K) for the treatment of hematologic malignancies. In addition to duvelisib the Company seeks to expand its pipeline through internal discovery research program and licensing of potential new product candidates or technologies discovered by third parties. The Company is conducting DUETTS (Duvelisib Trials in Hematologic Malignancies) a worldwide investigation of duvelisib in blood cancers.